Bladder Cancer News and Research

Latest Bladder Cancer News and Research

Aeterna Zentaris, Almac collaborate on study of AEZS-108 doxorubicin LHRH targeted conjugate compound

Aeterna Zentaris, Almac collaborate on study of AEZS-108 doxorubicin LHRH targeted conjugate compound

Researchers develop new assay test for bladder cancer

Researchers develop new assay test for bladder cancer

Bioniche announces issuance of new patents for MCC, Oligonucleotide technology platforms

Bioniche announces issuance of new patents for MCC, Oligonucleotide technology platforms

EC grants Allos Therapeutics' pralatrexate orphan medicinal product designation for CTCL treatment

EC grants Allos Therapeutics' pralatrexate orphan medicinal product designation for CTCL treatment

Predictive Biosciences completes $25M Series C financing round

Predictive Biosciences completes $25M Series C financing round

Fluorescent cancerous tumors for early detection

Fluorescent cancerous tumors for early detection

Telormedix initiates Phase I/II clinical study of TMX-101 for treating NMIBC

Telormedix initiates Phase I/II clinical study of TMX-101 for treating NMIBC

Researchers find new way to prevent blindness caused by retinitis pigmentosa

Researchers find new way to prevent blindness caused by retinitis pigmentosa

Final results from Phase 1 trial of OGX-427 for treating solid tumors presented at ASCO 2010

Final results from Phase 1 trial of OGX-427 for treating solid tumors presented at ASCO 2010

Promising clinical data on CDX-011 in metastatic melanoma presented at ASCO Annual Meeting

Promising clinical data on CDX-011 in metastatic melanoma presented at ASCO Annual Meeting

Aeterna Zentaris presents positive data from AEZS-108 Phase 2 study in ovarian cancer at ASCO 2010

Aeterna Zentaris presents positive data from AEZS-108 Phase 2 study in ovarian cancer at ASCO 2010

USC to present promising new findings in cancer research at 2010 ASCO

USC to present promising new findings in cancer research at 2010 ASCO

PEB's European licensee SDX completes clinical trial for prognostic gene signature for colorectal cancer

PEB's European licensee SDX completes clinical trial for prognostic gene signature for colorectal cancer

Promising results of ABRAXANE for bladder cancer support efficacy of nab-driven chemotherapy

Promising results of ABRAXANE for bladder cancer support efficacy of nab-driven chemotherapy

Radiation therapy may not improve chances of survival for bladder cancer patients: Study

Radiation therapy may not improve chances of survival for bladder cancer patients: Study

FDA approves Cysview for detection of non-muscle-invasive papillary cancer of bladder

FDA approves Cysview for detection of non-muscle-invasive papillary cancer of bladder

FDA grants orphan drug designation to pralatrexate for treatment of advanced TCC of urinary bladder

FDA grants orphan drug designation to pralatrexate for treatment of advanced TCC of urinary bladder

Tengion reports net loss attributable to common stockholders of $14.33 per share for first-quarter 2010

Tengion reports net loss attributable to common stockholders of $14.33 per share for first-quarter 2010

Cancer Research UK launches new cancer centre in Leeds

Cancer Research UK launches new cancer centre in Leeds

Celldex Therapeutics commences screening in CDX-1307 Phase 2 study for bladder cancer

Celldex Therapeutics commences screening in CDX-1307 Phase 2 study for bladder cancer

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.